Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesRxsight Inc

Rxsight Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
4.54 USD 0.00(0%)
Last update at 2026-11-06T21:00:00Z
VOLUME
948254
Market Cap
2443.70M

Momentum Score

…

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
4.36
Low
4.60
High
52 Week Price Range
20.66
Low
66.54
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Rxsight Inc develops and commercializes adjustable intraocular lenses that allow postoperative refractive tuning for cataract patients. Long-term growth drivers include an aging population driving cataract procedures, potential uptake of premium lenses that may improve visual outcomes, and broader clinical adoption and reimbursement expansion. The business may appeal to investors seeking exposure to a device with a differentiated value proposition in a large procedure market.

Key investment risks include execution and commercialization challenges, competition from standard and emerging IOL technologies, regulatory and reimbursement uncertainty, and the potential need for additional financing to support growth.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
4.54
Dividend Yield
-
Revenue TTM
101.10M
Revenue Per Share
2.83
Gross Profit TTM
21.33M
Debt / Equity
0.02
ROE
-28.81%
Net Debt
-6.68M
ROCE
-39.17%
Diluted EPS TTM
-1.24

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -66.75M -48.68M 27.63M 126.24M
Net income -66.76M -48.69M 27.57M 126.22M
Selling general administrative 58.66M 32.80M 15.18M 15.20M
Gross profit 21.33M 4.52M 1.71M -1.82M
Reconciled depreciation 4.02M 3.99M 4.01M 3.93M
Ebit -63.32M -52.79M -35.41M -46.07M
Ebitda -61.80M -52.73M -30.85M -40.35M
Depreciation and amortization 1.52M 0.05M 4.55M 5.72M
Non operating income net other 1.52M 2.77M - -
Operating income -63.32M -52.79M -35.41M -46.07M
Other operating expenses 112.32M 75.38M 50.08M 48.83M
Interest expense 4.95M 3.68M 0.51M 0.03M
Tax provision 0.01M 0.01M 0.06M 0.02M
Interest income 1.52M 0.05M 0.54M 2.31M
Net interest income -3.43M -3.63M 0.03M 2.28M
Income tax expense 0.01M 0.01M 0.06M 0.02M
Total revenue 49.01M 22.59M 14.68M 2.24M
Total operating expenses 84.65M 57.30M 37.11M 44.77M
Cost of revenue 27.68M 18.08M 12.97M 4.06M
Total other income expense net -3.43M 4.11M 63.04M 172.31M
Net income from continuing ops -66.76M -48.69M 27.57M 126.22M
Net income applicable to common shares -66.76M -48.69M 3.37M 26.13M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 182.55M 150.16M 192.72M 100.68M 110.43M
Other current assets 3.52M 2.96M 4.07M 1.37M 1.52M
Total liab 22.19M 60.26M 54.48M 398.21M 415.04M
Total stockholder equity 160.36M 89.90M 138.24M -297.53M -304.61M
Other current liab 13.19M 11.32M 7.24M 8.75M 4.89M
Common stock 0.04M 0.03M 0.03M 80.78M 56.42M
Capital stock 0.04M 0.03M 0.03M 80.78M 56.42M
Retained earnings -594.64M -546.03M -479.28M -430.59M -419.86M
Other liab - - - 136.89M 189.68M
Other assets - 1.53M 0.93M 0.57M 0.98M
Cash 9.69M 11.83M 24.36M 13.99M 7.96M
Total current liabilities 20.90M 17.24M 11.08M 11.60M 8.46M
Current deferred revenue 2.04M 1.35M 0.62M 0.44M 0.38M
Net debt -6.68M 33.16M 20.57M 16.76M -2.44M
Short term debt 1.80M 1.97M 1.53M 1.27M 0.99M
Short long term debt total 3.01M 44.99M 44.93M 30.75M 5.52M
Other stockholder equity 754.97M 636.00M 424.79M 52.28M 58.78M
Property plant equipment - 10.14M 11.22M 18.61M 19.25M
Total current assets 168.41M 134.56M 176.29M 81.50M 90.20M
Net tangible assets - 89.90M 138.24M -430.59M -419.81M
Short term investments 117.49M 93.97M 134.97M 54.98M 72.71M
Net receivables 20.28M 10.96M 4.86M 2.87M 0.79M
Long term debt - 40.17M 43.40M 24.40M -
Inventory 17.42M 14.84M 8.03M 8.29M 7.22M
Accounts payable 3.86M 2.60M 1.69M 1.13M 2.20M
Accumulated other comprehensive income -0.01M -0.10M -0.02M -0.00M 0.05M
Common stock total equity - 0.03M 0.03M 80.78M 56.42M
Retained earnings total equity - -546.03M -479.28M - -
Non currrent assets other 0.15M 1.53M 0.93M 0.57M 0.98M
Non current assets total 14.14M 15.61M 16.43M 19.18M 20.23M
Capital lease obligations 3.01M 4.83M 5.17M 6.35M 5.52M
Long term debt total - - 43.40M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments 42.34M -79.97M 18.13M -2.39M
Change to liabilities 5.45M 4.24M -0.95M 1.13M
Total cashflows from investing activities 39.95M -81.91M 15.59M -5.87M
Net borrowings -0.14M 14.87M 24.86M -0.18M
Total cash from financing activities 6.33M 137.34M 25.24M 1.33M
Change to operating activities 5.60M 0.87M -3.51M 1.16M
Net income -66.76M -48.69M 27.57M 126.22M
Change in cash -12.58M 10.72M 5.62M -45.15M
Begin period cash flow 25.17M 14.46M 8.83M 53.98M
End period cash flow 12.60M 25.17M 14.46M 8.83M
Total cash from operating activities -58.85M -44.71M -35.20M -40.62M
Issuance of capital stock 6.05M 119.58M - -
Depreciation 4.02M 3.99M 4.01M 3.93M
Change to inventory -7.55M -2.11M -1.31M -5.47M
Change to account receivables -6.09M -2.00M -2.08M -0.79M
Sale purchase of stock -0.59M 121.93M - -
Other cashflows from financing activities 0.40M 17.79M 25.38M 1.51M
Change to netincome 12.15M 7.22M -59.03M -166.80M
Capital expenditures 2.39M 1.94M 2.54M 4.09M
Change receivables -6.09M -2.00M - -
Cash flows other operating 0.93M -7.81M - -
Cash and cash equivalents changes -12.57M 10.73M - -
Change in working capital -7.41M -2.68M -7.85M -3.97M
Stock based compensation 11.40M 7.58M 4.18M 4.60M
Other non cash items -0.10M 0.49M 0.09M -171.40M
Free cash flow -61.24M -46.65M -37.74M -44.70M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RXST
Rxsight Inc		 -
-%		 4.54 - 172.41 22.15 13.34 9.08 -7.70
ABT
Abbott Laboratories		 -0.03
0.03%		 109.93 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 -3.04
2.90%		 101.80 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -9.21
2.75%		 325.87 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -2.15
4.12%		 49.85 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Rxsight Inc

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

100 Columbia, Aliso Viejo, CA, United States, 92656

949 521 7830

https://www.rxsight.com

374

Name Title Year Born
Dr. Ronald M. Kurtz M.D. Pres, CEO & Director 1963
Ms. Shelley B. Thunen CFO & Assistant Sec. 1954
Dr. Ilya Goldshleger Ph.D. Chief Operating Officer 1975
Mr. Eric J. Weinberg Chief Commercial Officer 1961
Rebecca Williston VP of Accounting & Fin. NA
Mr. Matt Haller Ph.D. Chief Technology Officer NA
Steve Everly VP of US Sales NA
Mr. Roy Freeman VP of Marketing NA
Caroline Vaughn VP of HR NA
Scott Gaines Sr. VP of Commercial Operations & Bus. Process NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…